Helus Pharma Inc. (HELP)

$7.73 -1.24 (-13.82%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 864,772
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterate...

Industry: Biotechnology
Sector: Healthcare
Phone: 908-764-8385
Website: cybin.com
Address:
100 King Street West, Suite 5600, Toronto, Canada
Marcelline
Marcelline May. 19 at 10:11 PM
$HELP we all have waited this long, why be negative? Crunch time soon. Dont stress over peas when there are billions on the table.
0 · Reply
kev90123
kev90123 May. 19 at 9:13 PM
$HELP The Board is going to enjoy their steak tonight (again) that you all paid for.
0 · Reply
everup
everup May. 19 at 8:01 PM
$HELP horrible, how many cents is this pos now pre split? Dime or Nickel?
0 · Reply
kev90123
kev90123 May. 19 at 7:55 PM
$HELP
0 · Reply
ChristopherMcC
ChristopherMcC May. 19 at 3:53 PM
$HELP went out to enjoy the sun for a few days...oh, only a 20% drop? On what?
0 · Reply
DJTHollaAtMe
DJTHollaAtMe May. 19 at 3:03 PM
$HELP Oversold af. Total BS.
0 · Reply
kev90123
kev90123 May. 19 at 2:20 PM
$HELP Paul Glavine probably out on his yacht today that he bought with all of your "investments"
0 · Reply
everup
everup May. 19 at 2:15 PM
$HELP all time lows..hellll yea
0 · Reply
kev90123
kev90123 May. 19 at 2:13 PM
$HELP
0 · Reply
FruitOs
FruitOs May. 19 at 1:43 PM
$HELP Fuck you Helus. Just fuck you
3 · Reply
Latest News on HELP
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Apr 30, 2026, 7:17 PM EDT - 19 days ago

CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference

Apr 30, 2026, 7:30 AM EDT - 19 days ago

Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference

Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Apr 28, 2026, 7:30 AM EDT - 21 days ago

Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan

Apr 23, 2026, 7:30 AM EDT - 26 days ago

Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan

How Trump's psychedelics executive order could unlock stalled cannabis reform

Apr 20, 2026, 2:05 PM EDT - 4 weeks ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI CMPS DFTX GHRS

Helus ‘welcomes’ Executive Order for accelerating psychedelic research

2026-04-20T14:47:00.000Z - 4 weeks ago

Helus ‘welcomes’ Executive Order for accelerating psychedelic research

Helus Pharma announces Cola is stepping down as CEO, appoints So as Interim CEO

2026-04-20T12:41:24.000Z - 4 weeks ago

Helus Pharma announces Cola is stepping down as CEO, appoints So as Interim CEO

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions

Apr 20, 2026, 8:15 AM EDT - 4 weeks ago

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions

Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer

Apr 20, 2026, 8:00 AM EDT - 4 weeks ago

Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

Apr 20, 2026, 6:43 AM EDT - 4 weeks ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS DFTX ENVB GHRS

Helus Pharma appoints Kramer as Senior Vice President, Medical Affairs

2026-04-16T11:38:27.000Z - 4 weeks ago

Helus Pharma appoints Kramer as Senior Vice President, Medical Affairs

BMY

Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs

Apr 16, 2026, 7:30 AM EDT - 4 weeks ago

Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs

Helus Pharma initiated with a Buy at TD Cowen

2026-04-13T09:50:28.000Z - 5 weeks ago

Helus Pharma initiated with a Buy at TD Cowen

Cybin Slides: Corporate presentation

Mar 27, 2026, 8:00 AM EDT - 7 weeks ago

Cybin Slides: Corporate presentation

Helus Pharma appoints Conwell as Chief People Officer

2026-03-12T11:46:37.000Z - 2 months ago

Helus Pharma appoints Conwell as Chief People Officer

ACRS

Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

Mar 12, 2026, 7:30 AM EDT - 2 months ago

Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

Helus Pharma announces results in Phase 2 signal detection study of HLP004

2026-03-05T13:10:05.000Z - 2 months ago

Helus Pharma announces results in Phase 2 signal detection study of HLP004

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Mar 5, 2026, 7:30 AM EST - 2 months ago

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Cybin Transcript: Study result

Mar 5, 2026, 7:30 AM EST - 2 months ago

Cybin Transcript: Study result

Cybin Press release: Study result

Mar 5, 2026, 7:30 AM EST - 2 months ago

Cybin Press release: Study result

Cybin Slides: Study result

Mar 5, 2026, 7:30 AM EST - 2 months ago

Cybin Slides: Study result

Helus Pharma appoints Freda Lewis-Hall to Board, Chair of Advisory Committee

2026-02-24T13:04:49.000Z - 3 months ago

Helus Pharma appoints Freda Lewis-Hall to Board, Chair of Advisory Committee

PFE

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Feb 24, 2026, 7:45 AM EST - 3 months ago

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Helus Pharma announces Phase 2a study of SPL026 met primary endpoint

2026-02-17T12:41:20.000Z - 3 months ago

Helus Pharma announces Phase 2a study of SPL026 met primary endpoint

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

Feb 17, 2026, 7:30 AM EST - 3 months ago

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

Cybin Earnings release: Q3 2026

Feb 13, 2026, 12:30 PM EST - 3 months ago

Cybin Earnings release: Q3 2026

Helus Pharma reports Q3 net loss $42.7M vs. $7.5M last year

2026-02-13T12:35:56.000Z - 3 months ago

Helus Pharma reports Q3 net loss $42.7M vs. $7.5M last year

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Feb 13, 2026, 7:31 AM EST - 3 months ago

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Dec 30, 2025, 3:33 PM EST - 5 months ago

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Cybin Registration statement: Registration Filing

Dec 19, 2025, 7:00 AM EST - 5 months ago

Cybin Registration statement: Registration Filing

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Dec 18, 2025, 12:29 PM EST - 5 months ago

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Cybin Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 7:30 AM EST - 6 months ago

Cybin Transcript: Jefferies London Healthcare Conference 2025

Cybin Earnings Call Transcript: Q2 2026

Nov 13, 2025, 8:00 AM EST - 6 months ago

Cybin Earnings Call Transcript: Q2 2026

Cybin Earnings release: Q2 2026

Nov 13, 2025, 8:00 AM EST - 6 months ago

Cybin Earnings release: Q2 2026

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 13, 2025, 7:20 AM EST - 6 months ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 7:30 AM EST - 6 months ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Cybin Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 4:30 PM EST - 6 months ago

Cybin Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 6, 2025, 7:30 AM EST - 6 months ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Cybin Transcript: Future of Health Summit 2025

Nov 5, 2025, 2:00 PM EST - 6 months ago

Cybin Transcript: Future of Health Summit 2025

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 7:30 AM EST - 6 months ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Nov 3, 2025, 7:30 AM EST - 7 months ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 31, 2025, 4:19 PM EDT - 7 months ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Cybin Announces $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 7 months ago

Cybin Announces $175 Million Registered Direct Offering

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Oct 21, 2025, 8:00 AM EDT - 7 months ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 23, 2025, 5:00 PM EDT - 8 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Cybin Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 17, 2025, 9:20 AM EDT - 8 months ago

Cybin Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Cybin Registration statement: Registration Filing

Sep 17, 2025, 8:00 AM EDT - 8 months ago

Cybin Registration statement: Registration Filing

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 11, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Cybin Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 11:00 AM EDT - 9 months ago

Cybin Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 8, 2025, 7:30 AM EDT - 9 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Cybin Transcript: Cantor Global Healthcare Conference 2025

Sep 5, 2025, 10:20 AM EDT - 9 months ago

Cybin Transcript: Cantor Global Healthcare Conference 2025

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:30 AM EDT - 9 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 9 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Cybin Announces Senior Leadership Changes

Sep 2, 2025, 7:30 AM EDT - 9 months ago

Cybin Announces Senior Leadership Changes

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 26, 2025, 7:30 AM EDT - 9 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Announces Results of Annual Meeting of Shareholders

Aug 18, 2025, 5:30 PM EDT - 9 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Cybin Transcript: AGM 2025

Aug 18, 2025, 10:00 AM EDT - 9 months ago

Cybin Transcript: AGM 2025

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 13, 2025, 5:30 PM EDT - 9 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Cybin Earnings release: Q1 2026

Aug 13, 2025, 4:00 PM EDT - 9 months ago

Cybin Earnings release: Q1 2026

Cybin Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 2:30 PM EDT - 10 months ago

Cybin Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 7, 2025, 7:30 AM EDT - 10 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:30 AM EDT - 10 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Cybin Registration statement: Registration Filing

Jul 31, 2025, 8:00 AM EDT - 10 months ago

Cybin Registration statement: Registration Filing

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 17, 2025, 7:30 AM EDT - 10 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jul 1, 2025, 11:19 AM EDT - 11 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Earnings release: Q4 2025

Jul 1, 2025, 12:00 AM EDT - 11 months ago

Cybin Earnings release: Q4 2025

Cybin Annual report: Q4 2025

Jul 1, 2025, 12:00 AM EDT - 11 months ago

Cybin Annual report: Q4 2025

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 10:03 PM EDT - 11 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 9:27 PM EDT - 11 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 13, 2025, 7:45 AM EDT - 1 year ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 12, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 11, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Jun 3, 2025, 7:30 AM EDT - 1 year ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Cybin Transcript: Fireside Chat

May 29, 2025, 11:00 AM EDT - 1 year ago

Cybin Transcript: Fireside Chat

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 22, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 20, 2025, 7:30 AM EDT - 1 year ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 15, 2025, 7:30 AM EDT - 1 year ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

Marcelline
Marcelline May. 19 at 10:11 PM
$HELP we all have waited this long, why be negative? Crunch time soon. Dont stress over peas when there are billions on the table.
0 · Reply
kev90123
kev90123 May. 19 at 9:13 PM
$HELP The Board is going to enjoy their steak tonight (again) that you all paid for.
0 · Reply
everup
everup May. 19 at 8:01 PM
$HELP horrible, how many cents is this pos now pre split? Dime or Nickel?
0 · Reply
kev90123
kev90123 May. 19 at 7:55 PM
$HELP
0 · Reply
ChristopherMcC
ChristopherMcC May. 19 at 3:53 PM
$HELP went out to enjoy the sun for a few days...oh, only a 20% drop? On what?
0 · Reply
DJTHollaAtMe
DJTHollaAtMe May. 19 at 3:03 PM
$HELP Oversold af. Total BS.
0 · Reply
kev90123
kev90123 May. 19 at 2:20 PM
$HELP Paul Glavine probably out on his yacht today that he bought with all of your "investments"
0 · Reply
everup
everup May. 19 at 2:15 PM
$HELP all time lows..hellll yea
0 · Reply
kev90123
kev90123 May. 19 at 2:13 PM
$HELP
0 · Reply
FruitOs
FruitOs May. 19 at 1:43 PM
$HELP Fuck you Helus. Just fuck you
3 · Reply
kev90123
kev90123 May. 19 at 12:43 PM
$HELP @HelusPharmaIR are you breaking 4 dollars today?
0 · Reply
Marcelline
Marcelline May. 19 at 1:13 AM
$HELP adjunctive treatment and shorter sessions
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 May. 19 at 12:34 AM
$HELP perfect distribution right along volume shelf. Likely candidate for low 3s. HAD MANAGEMENT NOT FIRED THE CEO THE MONDAY AFTER THE EXECUTIVE ORDER…unbelievable. Dumped this trash weeks ago after holding for 5 years.
1 · Reply
Solomonwisdom7
Solomonwisdom7 May. 18 at 11:39 PM
$HELP Why revolutionary?
0 · Reply
DJTHollaAtMe
DJTHollaAtMe May. 18 at 10:43 PM
$HELP Going to bring about revolutionary medicine. Just wait.
1 · Reply
kev90123
kev90123 May. 18 at 3:39 PM
$HELP @HelusPharmaIR just printed themselves another month's worth of their 7 figure salaries on the backs of current investors.
0 · Reply
everup
everup May. 18 at 3:20 PM
$HELP all the low let's gooo piece of sh
0 · Reply
Solomonwisdom7
Solomonwisdom7 May. 18 at 2:36 PM
$HELP I’m keeping an eye on this as an investment opportunity but I wouldn’t be surprised if it went down to high $3’s or low $4’s. There does not seem to be much trust in the leadership right now.
0 · Reply
FruitOs
FruitOs May. 18 at 1:45 PM
$HELP keep raising money by screwing everyone over! Good job guys! Thanks for stealing my money!
1 · Reply
kev90123
kev90123 May. 18 at 1:42 PM
$HELP ATM doing work! @HelusPharmaIR
0 · Reply
FruitOs
FruitOs May. 18 at 1:42 PM
$HELP wow the 50th red day in a row, what a suprise. Great management. Really care about their loyal shareholders.
0 · Reply
KeepLossesSmall
KeepLossesSmall May. 18 at 1:23 PM
$DFTX and $CMPS has been up decently especially after Trumps order. Why are $HELP and $ATAI lagging so much? I know Cybin has always been a POS but I thought ATAI was legit with a dedicated CEO who is always buying never selling.
2 · Reply